Arcus Biosciences, Inc. (RCUS)
29.66
-0.47
(-1.56%)
USD |
NYSE |
Sep 04, 16:00
29.66
0.00 (0.00%)
Pre-Market: 20:00
Arcus Biosciences SG&A Expense (TTM) : 106.00M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 106.00M |
| March 31, 2026 | 111.00M |
| December 31, 2025 | 110.00M |
| September 30, 2025 | 112.00M |
| June 30, 2025 | 115.00M |
| March 31, 2025 | 116.00M |
| December 31, 2024 | 120.00M |
| September 30, 2024 | 121.00M |
| June 30, 2024 | 121.00M |
| March 31, 2024 | 119.00M |
| December 31, 2023 | 117.00M |
| September 30, 2023 | 115.90M |
| June 30, 2023 | 112.19M |
| March 31, 2023 | 110.03M |
| December 31, 2022 | 104.00M |
| September 30, 2022 | 99.40M |
| June 30, 2022 | 89.45M |
| March 31, 2022 | 80.44M |
| Date | Value |
|---|---|
| December 31, 2021 | 72.29M |
| September 30, 2021 | 61.78M |
| June 30, 2021 | 56.61M |
| March 31, 2021 | 51.22M |
| December 31, 2020 | 42.40M |
| September 30, 2020 | 36.21M |
| June 30, 2020 | 32.79M |
| March 31, 2020 | 27.27M |
| December 31, 2019 | 25.23M |
| September 30, 2019 | 22.25M |
| June 30, 2019 | 18.07M |
| March 31, 2019 | 15.61M |
| December 31, 2018 | 13.57M |
| September 30, 2018 | 12.40M |
| June 30, 2018 | 10.69M |
| March 31, 2018 | 7.239M |
| December 31, 2017 | 4.31M |
| September 30, 2017 | 1.862M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Halozyme Therapeutics, Inc. | 238.00M |
| AVITA Medical, Inc. | 81.89M |
| Iovance Biotherapeutics, Inc. | 149.18M |
| Editas Medicine, Inc. | 45.51M |
| Recursion Pharmaceuticals, Inc. | 151.41M |